Provided by Tiger Trade Technology Pte. Ltd.

Corbus Pharmaceuticals

6.92
-1.1600-14.36%
Pre-market: 6.87-0.0500-0.72%08:56 EDT
Volume:3.76M
Turnover:25.36M
Market Cap:133.84M
PE:-1.14
High:8.08
Open:8.08
Low:6.33
Close:8.08
52wk High:20.56
52wk Low:6.33
Shares:19.34M
Float Shares:17.42M
Volume Ratio:1.41
T/O Rate:21.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0889
EPS(LYR):-5.9000
ROE:-95.58%
ROA:-53.00%
PB:1.31
PE(LYR):-1.17

Loading ...

Corbus Pharmaceuticals Holdings Inc. Stock Slides 14.4%, Underperforms Peers

Dow Jones
·
16 hours ago

Wedbush Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)

TIPRANKS
·
Yesterday

Analysts’ Top Healthcare Picks: Corbus Pharmaceuticals (CRBP), Definium Therapeutics (DFTX)

TIPRANKS
·
Yesterday

Corbus Pharmaceuticals Price Target Maintained with a $35.00/Share by HC Wainwright & Co.

Dow Jones
·
Yesterday

Corbus Pharmaceuticals: Buy Rating Reaffirmed as CRB-913 Phase 1b Data Impress; $38 Price Target Maintained

TIPRANKS
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

Corbus Pharma Reports Positive Top-Line Data from Weight-Loss Drug Study

Dow Jones
·
Sep 14

Corbus Says Phase 1b Canyon-1 Trial Shows CRB-913 Delivers 5% Mean Weight Loss at 12 Weeks in Obesity Study

Reuters
·
Sep 14

Corbus Pharmaceuticals Holdings, - Expects to Initiate Phase 2 Monotherapy Study for Crb-913 in H1 2027

THOMSON REUTERS
·
Sep 14

Corbus Pharmaceuticals Announces Positive Topline Data from Canyon-1 Study of Daily Oral Crb-913 for the Treatment of Obesity

THOMSON REUTERS
·
Sep 14

Corbus Pharmaceuticals Holdings, - Crb-913 Treatment Discontinuations Due to Adverse Events Range from 3.1% to 13.1%

THOMSON REUTERS
·
Sep 14

Corbus Pharmaceuticals Holdings, - Crb-913 Achieves 5% Mean Weight Loss at 60 Mg After 12 Weeks

THOMSON REUTERS
·
Sep 14

Corbus Pharmaceuticals Holdings, - Crb-913 Well Tolerated with Favorable Psychiatric and Gi Adverse Event Profile

THOMSON REUTERS
·
Sep 14

Corbus Pharmaceuticals Holdings, - Crb-913 Data Support Potential for New Class of Oral Non-Incretin Obesity Medicines

THOMSON REUTERS
·
Sep 14

Stocks to Watch: Corbus Pharmaceuticals, Scholar Rock

Dow Jones
·
Sep 12

Corbus Pharmaceuticals Stock Surges Ahead of Drug Data Readout

Dow Jones
·
Sep 12

Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 12

Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

GlobeNewswire
·
Sep 12

Corbus Pharmaceuticals Holdings Inc. Stock Sheds 7.0%, Underperforms Peers

Dow Jones
·
Sep 11

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioLife Solutions (BLFS) and Corbus Pharmaceuticals (CRBP)

TIPRANKS
·
Sep 09